Locations:
SearchSearch our Cancer Clinical Trials Database for a full listing of all open and accruing studies
Lymphoma, Mantle Cell
KITE 1415
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)
View full trial information.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Myeloproliferative Neoplasms
CLGN 1917
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and Without Red Blood Cell-Transfusion Dependence
View full trial information.
Leukemia, Acute Myeloid (AML), Prostate
ABBV 1917
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects with Metastatic Castrate-Resistant Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML)
View full trial information.
Myelodysplastic Syndrome (MDS)
BBI 1Y17
A Phase 1 Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients with Advanced Malignancies
View full trial information.
Sickle Cell Disease (SCD)
CTN 1507
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
View full trial information.
Hematologic Malignancy
CASE 16Z17
The Effects of Pre-Transplant Music Therapy for Patients Undergoing Hematopoietic Stem Cell
View full trial information.
Search our Cancer Clinical Trials Database for a full listing of all open and accruing studies.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy